| heart failure | All results are NS for efficacy inferior to placebo in terms of Total mortality in VEST, 1998 inferior to placebo in terms of Sudden death in VEST, 1998 | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| OPC-8212 MRG, 1990 | vs placebo | | | Total mortality 0.00 [0.00; NaN] Worsening heart failure (requiring intervention) 0.14 [0.02; 1.12] Arrhythmia ∞ [NaN; ∞] Vertigo ∞ [NaN; ∞] | | VEST, 1998 | vs placebo | | Total mortality 1.16 [1.02; 1.33] Sudden death 1.26 [1.03; 1.54] | Myocardial infarction (fatal & non fatal) 1.41 [0.51; 3.90] Cardiac death 1.13 [0.98; 1.30] Worsening heart failure (requiring intervention) 0.95 [0.85; 1.05] | | VSG, 1993 | vs placebo | Total mortality 0.39 [0.21; 0.73] Sudden death 0.20 [0.06; 0.68] Cardiac death 0.36 [0.19; 0.68] Worsening heart failure (requiring intervention) 0.54 [0.31; 0.94] | | Myocardial infarction (fatal & non fatal) 1.00 [0.33; 3.04] Transplantation 0.46 [0.18; 1.19] Arrhythmia 2.99 [0.31; 28.52] |
| Trial | Treatments | Patients | Method |
|---|
| OPC-8212 MRG, 1990 | Vesnarinone 60mg/d (n=45) vs. placebo (n=48) | NYHA II-IV | double blind Parallel groups Sample size: 45/48 Primary endpoint: none FU duration: 3 months | | VEST, 1998 | Vesnarinone 30, 60mg/d (n=2550) vs. placebo (n=1283) | NYHA III,IV | double blind Parallel groups Sample size: 2550/1283 Primary endpoint: Total mortality FU duration: 9 months | | VSG, 1993 | Vesnarinone 60mg/d (n=-9) vs. placebo (n=-9) | NYHA II-IV | double blind Parallel groups Sample size: -9/-9 Primary endpoint: total mortality or major cardiovascular morbidity FU duration: 6 months |
|
